Structural analysis of the EGFR TK domain and potential implications for EGFR targeted therapy

International Journal of Oncology

Volumn 40, Issue 6, 2012, Pages 1763-1769

  Nie, Weiwei ^a   Tang, Lin ^a   Zhang, Haiyang ^b   Shao, Jiaqing ^a   Wang, Yucai ^a   Chen, Longbang ^a   Li, Donghai ^b   Guan, Xiaoxiang ^a  

^a MEDICAL SCHOOL OF NANJING UNIVERSITY   (China)

^b NANJING UNIVERSITY   (China)

Author keywords

Crystal structures; EGFR; EGFR mutations; TKI

Indexed keywords

AFATINIB; CABOZANTINIB; CETUXIMAB; CRIZOTINIB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE; ERLOTINIB; GEFITINIB; GUANOSINE TRIPHOSPHATASE; K RAS PROTEIN; NERATINIB; PANITUMUMAB; PHOSPHATIDYLINOSITOL 3 KINASE; RAF PROTEIN; RAS PROTEIN; SCATTER FACTOR RECEPTOR; STRESS ACTIVATED PROTEIN KINASE; TIVANTINIB;

ALPHA HELIX; AMINO TERMINAL SEQUENCE; AUTOPHOSPHORYLATION; BETA SHEET; CARBOXY TERMINAL SEQUENCE; CATALYSIS; CELL GROWTH; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; CONFORMATIONAL TRANSITION; CRYSTAL STRUCTURE; CYTOSKELETON; DNA SYNTHESIS; DRUG EFFICACY; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; EXON; GENE EXPRESSION; GENE MUTATION; HUMAN; HYDROGEN BOND; HYDROPHOBICITY; MOLECULARLY TARGETED THERAPY; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN PROTEIN INTERACTION; REVIEW; SIGNAL TRANSDUCTION; SOMATIC MUTATION; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS; CATALYTIC DOMAIN; CRYSTALLOGRAPHY, X-RAY; DRUG RESISTANCE, NEOPLASM; HUMANS; MODELS, MOLECULAR; MOLECULAR TARGETED THERAPY; MUTATION, MISSENSE; NEOPLASMS; PROTEIN BINDING; PROTEIN STRUCTURE, SECONDARY; QUINAZOLINES; QUINOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84861787457     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2012.1356     Document Type: Review

References (49)

1. Cai C, Peng Y, Buckley M, et al: Epidermal growth factor receptor activation in prostate cancer by three novel missense mutations. Oncogene 27: 3201-3210, 2008. (Pubitemid 351693177)
2. Voldborg BR, Damstrup L, Spang-Thomsen M and Poulsen HS: Epidermal growth factor receptor (EGFR) and EGFR mutations, function and possible role in clinical trials. Ann Oncol 8: 1197-1206, 1997. (Pubitemid 28164074)
3. Shigematsu H, Lin L, Takahashi T, et al: Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 97: 339-346, 2005. (Pubitemid 40425952)
4. Gazdar AF, Shigematsu H, Herz J and Minna JD: Mutations and addiction to EGFR: the Achilles 'heal' of lung cancers? Trends Mol Med 10: 481-486, 2004. (Pubitemid 39303620)
5. Robinson DR, Wu YM and Lin SF: The protein tyrosine kinase family of the human genome. Oncogene 19: 5548-5557, 2000.
6. Kumar A, Petri ET, Halmos B and Boggon TJ: Structure and clinical relevance of the epidermal growth factor receptor in human cancer. J Clin Oncol 26: 1742-1751, 2008.
7. Huse M and Kuriyan J: The conformational plasticity of protein kinases. Cell 109: 275-282, 2002. (Pubitemid 34606870)
8. Shigematsu H and Gazdar AF: Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancers. Int J Cancer 118: 257-262, 2006. (Pubitemid 41779062)
9. Sharma SV, Bell DW, Settleman J and Haber DA: Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer 7: 169-181, 2007.
10. Gazdar AF: Active and resistance mutations of EGFR inonsmall-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors active EGFR mutations in NSCLC. Oncogene 28: S24-S31, 2009.
11. Balak MN, Gong Y, Riely GJ, et al: Novel D761Y and common secondary T790M mutations in epidermal growth factor receptormutant lung adenocarcinomas with acquired resistance to kinase inhibitors. Clin Cancer Res 12: 6494-6501, 2006. (Pubitemid 44799723)
12. Chen YR, Fu YN, Lin CH, et al: Distinctive activation patterns in constitutively active and gefitinib-sensitive EGFR mutants. Oncogene 25: 1205-1215, 2006.
13. Costa DB, Halmos B, Kumar A, et al: BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations. PLoS Med 4: 1669-1680, 2007. (Pubitemid 350035456)
14. Bean J, Riely GJ, Balak M, et al: Acquired resistance to epidermal growth factor receptor kinase inhibitors associated with a novel T854A mutation in a patient with EGFR-mutant lung adenocarcinoma. Clin Cancer Res 14: 7519-7525, 2008.
15. John T, Liu G and Tsao M: Overview of molecular testing in nonsmall-cell lung cancer: mutational analysis, gene copy number, protein expression and other biomarkers of EGFR for the prediction of response to tyrosine kinase inhibitors. Oncogene 28: S14-S23, 2009.
16. Garriz A, Qiu HF, Dey M, Seo EJ, Dever TE and Hinnebusch AG: A network of hydrophobic residues impeding helix alpha c rotation maintains latency of kinase Gcn2, which phosphorylates the alpha subunit of translation initiation factor 2. Mol Cell Biol 29: 1592-1607, 2009.
17. Hubbard SR: Structural analysis of receptor tyrosine kinases. Prog Biophys Mol Biol 71: 343-358, 1999.
18. Johnston JB, Navaratnam S, Pitz MW, et al: Targeting the EGFR pathway for cancer therapy. Curr Med Chem 13: 3483-3492, 2006. (Pubitemid 44873742)
19. Stamos J, Sliwkowski MX and Eigenbrot C: Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor. J Biol 277: 46265-46272, 2002. (Pubitemid 35417619)
20. Wood ER, Truesdale AT, McDonald OB, et al: A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells. Cancer Res 64: 6652-6659, 2004. (Pubitemid 39297926)
21. Zhang X, Gureasko J, Shen K, Cole PA and Kuriyan J: An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor. Cell 125: 1137-1149, 2006. (Pubitemid 43866200)
22. Yun CH, Boggon TJ, Li Y, et al: Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity. Cancer Cell 11: 217, 2007.
23. Blair JA, Rauh D, Kung C, et al: Structure-guided development of affinity probes for tyrosine kinases using chemical genetics. Nat Chem Biol 3: 229-238, 2007. (Pubitemid 46440537)
24. Zhou W, Eran D, Chen L, et al: Crystal structure of EGFR 696-1022 T790M mutant covalently binding to WZ4002. Nature 462: 1070-1074, 2009.
25. Jura N, Endres NF, Engel K, et al: Mechanism for activation of the EGF receptor catalytic domain by the juxtamembrane segment. Cell 137: 1293-1307, 2009.
26. Frederick L, Wang XY, Eley G and James CD: Diversity and frequency of epidermal growth factor receptor mutations in human glioblastomas. Cancer Res 60: 1383-1387, 2000. (Pubitemid 30152011)
27. Rodrigues GA, Falasca M, Zhang Z, Ong SH and Schlessinger J: A novel positive feedback loop mediated by the docking protein Gab1 and phosphatidylinositol 3-kinase in epidermal growth factor receptor signaling. Mol Cell Biol 20: 1448-1459, 2000. (Pubitemid 30069264)
28. Zhang Z, Stiegler AL, Boggon TJ, Kobayashi S and Halmos B: EGFR-mutated lung cancer: a paradigm of molecular oncology. Oncotarget 1: 497-514, 2010.
29. Ishikawa N, Daigo Y, Takano A, et al: Increases of amphiregulin and transforming growth factor-α in serum as predictors of poor response to gefitinib among patients with advanced non-small cell lung cancers. Cancer Res 65: 9176, 2005.
30. Mirza A, Mustafa M, Talevich E and Kannan N: Co-conserved features associated with cis regulation of ErbB tyrosine kinases. PLoS One 5: e14310, 2010.
31. Dixit A, Torkamani A, Schork NJ and Verkhivker G: Computational modeling of structurally conserved cancer mutations in the RET and MET kinases: the impact on protein structure, dynamics, and stability. Biophys J 96: 858-874, 2009.
32. Bikker JA, Brooijmans N, Wissner A and Mansour TS: Kinase domain mutations in cancer: implications for small molecule drug design strategies. J Med Chem 52: 1493-1509, 2009.
33. Rosell R, Taron M, Reguart N, et al: Epidermal growth factor receptor activation: how exon 19 and 21 mutations changed our understanding of the pathway. Clin Cancer Res 12: 7222-7231, 2006. (Pubitemid 46095393)
34. Riely GJ, Politi KA, Miller VA, et al: Update on EGFR mutations in non-small cell lung cancer. Clin Cancer Res 12: 7232-7241, 2006.
35. Mitsudomi T and Yatabe Y: Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer. Cancer Sci 98: 1817-1824, 2007. (Pubitemid 350002184)
36. Jiang J, Greulich H, Janne PA, et al: Epidermal growth factor-independent transformation of Ba/F3 cells with cancer-derived epidermal growth factor receptor mutants induces gefitinibsensitive cell cycle progression. Cancer Res 65: 8968-8974, 2005. (Pubitemid 41377388)
37. Yun CH, Mengwasser KE, Toms AV, et al: The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc Natl Acad Sci USA 105: 2070-2075, 2008. (Pubitemid 351439466)
38. Nguyen KS, Kobayashi S and Costa DB: Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in nonsmall-cell lung cancers dependent on the epidermal growth factor receptor pathway. Clin Lung Cancer 10: 281-289, 2009.
39. Kwak EL, Sordella R, Bell DW, et al: Irreversible inhibitors of the EGFR receptor may circumvent acquired resistance to gefitinib. Proc Natl Acad Sci USA 102: 7665-7670, 2005.
40. Tsou HR, Overbeek-Klumpers EG, Hallett WA, et al: Optimization of 6, 7-disubstituted-4-(arylamino) quinoline-3-carbonitriles as orally active, irreversible inhibitors of human epidermal growth factor receptor-2 kinase activity. J Med Chem 48: 1107-1131, 2005. (Pubitemid 40270454)
41. Li D, Ambrogio L, Shimamura T, et al: BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. Oncogene 27: 4702-4711, 2008.
42. Yang C, Shih J, Chao T, et al: Use of BIBW 2992, a novel irreversible EGFR/HER2 TKI, to induce regression in patients with adenocarcinoma of the lung and active EGFR mutations: preliminary results of a single-arm phase II clinical trial. J Clin Oncol 26: S430, 2008.
43. Riely GJ, Marks J and Pao W: KRAS mutations in non-small cell lung cancer. Proc Am Thorac Soc 6: 201-205, 2009.
44. Wicki A, Herrmann R and Christofori G: KRAS in metastatic colorectal cancer. Swiss Med Wkly 140: w13112, 2010.
45. Trusolino L, Bertotti A and Comoglio PM: Met signalling: principles and functions in development, organ regeneration and cancer. Nat Rev Mol Cell Biol 11: 834-848, 2010.
46. Bogoyevitch MA and Kobe B: Uses for JNK: the many and varied substrates of the c-Jun N-terminal kinases. Microbiol Mol Biol Rev 70: 1061-1095, 2006. (Pubitemid 44958264)
47. Porter J: Small molecule c-Met kinase inhibitors: a review of recent patents. Expert Opin Ther Pat 20: 159-177, 2010.
48. Tang Z, Du R, Jiang S, et al: Dual MET-EGFR combinatorial inhibition against T790M-EGFR-mediated erlotinib-resistant lung cancer. Br J Cancer 99: 911-922, 2008.
49. Ratushny V, Astsaturov I, Burtness BA, Golemis EA and Silverman JS: Targeting EGFR resistance networks in head and neck cancer. Cell Signal 21: 1255-1268, 2009.